Evolus, INC

Evolus, Inc. announced robust second quarter 2026 financial results, including a 21% increase in net revenue and a third consecutive quarter of positive Adjusted EBITDA, leading to an improved full-year financial outlook.

Evolus, Inc. has expanded its strategic partnership with Symatese, securing exclusive rights to commercialize the Estyme injectable HA gel collection in Canada, Australia, and New Zealand.

Evolus, Inc. has entered into an exclusive agreement with IBSA to develop and commercialize Profhilo, a leading injectable for skin quality, in the United States.

Evolus, Inc. stockholders elected two Class II directors, ratified its auditor, and approved executive compensation at the 2026 Annual Meeting.

Evolus, Inc. announced its first quarter 2026 financial results, achieving its second consecutive quarter of positive Adjusted EBITDA and reaffirming its full-year outlook.

Evolus, Inc. announced the reclassification of Vikram Malik from a Class III to a Class II director to restore balance to its classified board structure.

Evolus, Inc. reported a 21.2% increase in net revenues for the three months ended June 30, 2026, driven by higher Jeuveau sales, while also addressing potential tariff impacts.

Evolus, Inc. announced its first-quarter 2026 financial results, reporting a 6.7% increase in net revenues to $73.1 million, driven by the launch of Evolysse and international growth of Jeuveau.

Evolus, Inc. reported increased net revenues in Q3 2025 driven by new product launches, but also saw a widening net loss and increased cash usage from operations.

Evolus, Inc. reported a wider net loss in the second quarter of 2025, driven by increased operating expenses and higher interest costs, despite the successful U.S. launch of its new Evolysse product line.

Evolus, Inc. announces its Q1 2025 financial results, highlighting a 15.5% increase in revenue compared to the same period last year, driven by higher sales volumes of Jeuveau.

Evolus, Inc. reports a 22.2% increase in net revenue for the third quarter of 2024, primarily driven by higher sales volumes of its flagship product, Jeuveau.

Evolus, a global performance beauty company, reported a net loss of $51.6 million for 2025, an increase from $50.4 million in 2024, despite an 11.6% revenue growth driven by Jeuveau sales and the U.S. launch of Evolysse Form and Smooth.

Evolus reports a 32% increase in net revenues for 2024, driven by higher sales volumes of Jeuveau, and anticipates launching Evolysse products in 2025.

Evolus, Inc.'s 10-K filing details the company's authorized capital stock, shareholder rights, and anti-takeover provisions.

Evolus officer Rui Avelar sold 3,119 shares of common stock to cover tax withholding obligations related to restricted stock unit awards.

Evolus, Inc. CEO David Moatazedi sold 13,669 shares of common stock to cover tax withholding obligations related to restricted stock unit awards.

Evolus, Inc. CEO David Moatazedi reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.

Evolus Chief Medical Officer Rui Avelar sold shares to cover tax obligations following the vesting of performance restricted stock units.

Evolus, Inc. Director Karah Parschauer was granted 45,559 restricted stock units, vesting on February 17, 2027.

Evolus, Inc. Director Brady Stewart was granted 45,559 restricted stock units, which will vest in February 2027.

Evolus, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, to be held virtually via live webcast.

Evolus, Inc. has filed a definitive proxy statement with the SEC.

Evolus, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to vote on the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation.

Evolus, Inc. has filed a definitive proxy statement with the SEC.

Evolus, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 6, 2024, to address director elections, auditor ratification, and employee stock purchase plan approval, among other items.

The Vanguard Group has amended its Schedule 13G filing for Evolus Inc., reporting zero beneficial ownership following an internal realignment.

Timothy P. Lynch has disclosed a 9.9% beneficial ownership stake in Evolus, Inc., holding 6,425,726 shares of common stock.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, filed an amended Schedule 13G disclosing a shared beneficial ownership of 8.85% in Evolus, Inc. common stock.

Caligan Partners LP and David Johnson have reported a 6.4% beneficial ownership stake in Evolus, Inc., totaling 4,138,943 shares of common stock.

Timothy P. Lynch has increased his beneficial ownership in Evolus, Inc. to 7.9% of the common stock, totaling 5,133,776 shares.

Timothy P. Lynch has disclosed a 6.3% beneficial ownership stake in Evolus, Inc. common stock.